3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Breast
1
Conditions
Gliosarcoma
22
Glioblastoma
22
Brain Neoplasms
16
Glioma
10
Astrocytoma
9
Oligodendroglioma
8
Central Nervous System Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
3
Carcinoma, Non-Small-Cell Lung
3
Sarcoma
2
Salivary Gland Neoplasms
2
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Medulloblastoma
2
Gastrointestinal Stromal Tumors
2
Esthesioneuroblastoma, Olfactory
2
Esophageal Neoplasms
2
Ependymoma
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Anus Neoplasms
2
Wilms Tumor
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Stomach Neoplasms
1
Spinal Cord Neoplasms
1
Small Cell Lung Carcinoma
1
Interventions
Doxorubicin
19
Ifosfamide
12
Radiotherapy
11
pembrolizumab
6
Nivolumab
6
Ipilimumab
6
pazopanib
4
Specimen Handling
4
Radiation
4
Gemcitabine
4
Docetaxel
4
CTLA-4 Antigen
4
Biopsy
4
Trabectedin
3
Sunitinib
3
Magnetic Resonance Spectroscopy
3
pegfilgrastim
2
liposomal doxorubicin
2
cabozantinib
2
brostallicin
2
X-Rays
2
Radiotherapy, Conformal
2
Radiation Dose Hypofractionation
2
Methotrexate
2
Imatinib Mesylate
2
Filgrastim
2
Etoposide
2
Diathermy
2
Cisplatin
2
Chemotherapy, Adjuvant
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Histiocytoma, Malignant Fibrous
×
Erlotinib Hydrochloride
×
Sarcoma
×
Clear all
NCT05827614
2026-01-23
POTENTIATE
Boundless Bio, Inc.
Phase 1
Active not recruiting
85 enrolled